1. The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir
- Author
-
C Nouts, M. Bonarek, Morlat P, I. Delevaux, N. Bernard, Fabrice Bonnet, Beylot J, and D. Lacoste
- Subjects
medicine.medical_specialty ,030505 public health ,Multivariate analysis ,Proportional hazards model ,business.industry ,Hazard ratio ,Public Health, Environmental and Occupational Health ,Dermatology ,Gastroenterology ,Surgery ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Infectious Diseases ,Indinavir ,Internal medicine ,medicine ,Pharmacology (medical) ,030212 general & internal medicine ,0305 other medical science ,Prospective cohort study ,business ,Adverse effect ,Viral load ,medicine.drug - Abstract
In order to determine prognostic factors associated with treatment failure (TF) in advanced HIV-infected patients treated with a regimen including indinavir, a prospective cohort study of 80 patients was set up between 1 March and 31 December 1996. TF time was calculated using the Kaplan–Meier method, from treatment induction to the first of the following events: treatment modification for adverse event or lack of significant virological and/or immunological response, AIDS-defining diagnosis or death. Date of point was 31 December 1998. Multivariate analysis was performed using a Cox model. At baseline, 60% of the patients were AIDS-free, median viral load and CD4+ count were respectively 4.8 log/ml and 79/μl. After a median follow-up of 26 months, 70% of the patients experienced a TF in a median time of 8 months. Seventy-two per cent presented an hyperbilirubinaemia (>2 mg/dl). In multivariate analysis, initial AIDS stage (hazard ratios [HR]=1.94, P=0.04) and digestive intolerance (HR=2.32, P=0.003) were predictive of TF. Conversely, hyperbilirubinaemia was associated with a better outcome (HR=0.35, P
- Published
- 2001
- Full Text
- View/download PDF